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Abstract
Chronic obstructive pulmonary disease (COPD)/emphysema risk groups are well defined and
screening allows for early identification of disease. The capability of exhaled volatile organic
compounds (VOCs) to detect emphysema, as found by computed tomography (CT) in current
and former heavy smokers participating in a lung cancer screening trial, was investigated. CT
scans, pulmonary function tests and breath sample collections were obtained from 204
subjects. Breath samples were analyzed with a proton-transfer reaction mass spectrometer
(PTR-MS) to obtain VOC profiles listed as ions at various mass-to-charge ratios (m/z). Using
bootstrapped stepwise forward logistic regression, we identified specific breath profiles as a
potential tool for the diagnosis of emphysema, of airflow limitation or gas-exchange
impairment. A marker for emphysema was found at m/z 87 (tentatively attributed to
2-methylbutanal). The area under the receiver operating characteristic curve (ROC) of this
marker to diagnose emphysema was 0.588 (95% CI 0.453–0.662). Mass-to-charge ratios m/z
52 (most likely chloramine) and m/z 135 (alkyl benzene) were linked to obstructive disease
and m/z 122 (most probably alkyl homologs) to an impaired diffusion capacity. ROC areas
were 0.646 (95% CI 0.562–0.730) and 0.671 (95% CI 0.524–0.710), respectively. In the
screening setting, exhaled VOCs measured by PTR-MS constitute weak markers for
emphysema, pulmonary obstruction and impaired diffusion capacity.
S Online supplementary data available from stacks.iop.org/JBR/5/046009/mmedia
1. Introduction
For chronic obstructive pulmonary disease (COPD), the
groups at risk are well defined and screening may allow
identification of subjects in an early stage of the disease [1].
Emphysema, one of the components of COPD, is diagnosed
via computed tomography (CT), by highlighting the areas with
an abnormally low density [2]. Tissue density is expressed
in Hounsfield units (HU) and the extent of emphysema is
expressed as the percentage of the total lung volume below a
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density threshold [3]. The major drawbacks of CT scans are
equipment immobility and radiation burden, although recent
developments reduced the radiation dose significantly from
5 to 1 millisievert (mSv) [4]. Pulmonary function testing
(PFT) is done easily and at lower costs, but the often used
parameters from spirometry/flow-volume curves cannot detect
emphysema when it is present without airflow limitation [5–7].
In the last decade, there has been an increased interest in
exhaled breath analysis because the method is non-invasive,
presents minimal risk to patients and allows large numbers
of subjects to be investigated [8, 9]. The human breath
contains volatile organic compounds (VOCs), which can serve
as biomarkers. Proton-transfer reaction mass spectrometry
(PTR-MS) is a promising tool for a rapid on-line determination
of exhaled VOC profiles [10, 11].
The aim of the study presented in this paper was to
explore breath analysis as a non-invasive method for the early
detection of emphysema in heavy smokers at risk to develop
COPD. The hypothesis is that emphysema is characterized by
inflammation, which alters the composition of the exhaled air.
The detection of airflow limitation or impaired gas-exchange
was a secondary goal.
2. Methods
2.1. Subjects
The subjects included participated in the ‘NELSON-
project’, a Dutch–Belgian multi-center lung cancer screening.
Participants were current and former male smokers between 50
and 75 years old, who smoked >15 cigarettes per day during
>25 years, or >10 cigarettes per day during >30 years and
had <10 years of smoking cessation [12]. No prior diagnosis
of either obstruction or emphysema was known. The trial was
approved by the Dutch ministry of health (approval number
2000/04WBO). Subjects gave written informed consent. A
waiver was received for the current analysis.
2.2. CT Scanning and calculation of emphysema scores
CT scanning was performed by a 16-detector-row scanner
(Mx8000 IDT or Brilliance 16P, Philips Medical Systems,
Cleveland, OH) at 16 × 0.75 mm collimation. Exposure
settings were 30 mAs at 120 kVp for patients 80 kg and
30 mAs at 140 kVp for those >80 kg. Images were
reconstructed at 1.0 mm slice thickness, at 0.7 mm increment,
at 512 × 512 matrix and using a moderately soft filter (Philips
‘B’). All CT scans were analyzed for the presence and extent of
emphysema using in-house developed software, imageXplorer
(iX), Image Sciences Institute, Utrecht, the Netherlands)
[13–15].
Areas with an attenuation < −950 HU ( = tissue density
<50 gr l−1) were considered to represent emphysema [3].
The emphysema score (ES) is the volume with attenuation
below that threshold, expressed as percentage of the total
lung volume. An ES  1% was considered as abnormal
[16]. This threshold represents developing emphysema, as
no emphysema should be present in healthy subjects.
2.3. Pulmonary function tests
Pulmonary function tests included the forced expiratory
volume in 1 s (FEV1), forced vital capacity (FVC), the
diffusing capacity for carbon monoxide (Dlco) and alveolar
volume (VA). Tests were conducted according to ERS
guidelines, and abnormal pulmonary function values were
defined as  −1.64 residual standard deviations below
reference values [17].
On the day of the tests, participants refrained from
smoking. They rested for 15 min upon arrival after which
spirometry was performed, followed by flow–volume curves.
The best of three attempts was selected for analysis. No
reversibility testing was done. For descriptive purposes
only, subjects were staged according to updated GOLD
guidelines [18].
Diffusing capacity measurements were carried out after
the spirometry and flow–volume curves. The inhalation
mixture contained 0.3% CO and 10% He with balance air. A
breath-holding period of 10 s was used. Dlco was not corrected
for haemoglobulin [19]. Dlco was corrected for COHb and
divided by the alveolar volume (Dlco/VA).
2.4. Exhaled breath sampling and measurement of VOCs
Exhaled single breath samples were collected in Tedlar bags
before PFT, using the method for the measurement of exhaled
nitric oxide [20]. The sampling device is described in detail
elsewhere [21]. In addition to each breath sample, the inhaled
room air was also analyzed and if was found polluted, the
corresponding breath sample was discarded.
The analysis of exhaled compounds was performed
with a proton transfer reaction mass spectrometer (PTR-MS)
[21–23]. Briefly, gases are ionized with H3O+ ions, after
which the product ions are mass analyzed and detected with
a quadrupole mass spectrometer. VOCs are listed as ions at
various mass-to-charge ratios (m/z).
The system was calibrated by mixing a variable flow of
air free of hydrocarbons (by passing it through a catalyst at
350 ◦C) with a fixed flow of 0.3 l h−1 of a gas mixture of
methanol, acetaldehyde, acetone, isoprene, benzene, toluene
and xylene (molecular weights ranging from 32 to 106 amu)
in concentrations of 1 ppmv (±5%) (Linde, Dieren, the
Netherlands). In this way, calibration factors are obtained for
these compounds converting ion intensity (in ncps, normalized
counts per seconds) to gas mixing ratios (in ppbv, part per
billion volume). From these conversion factors, the calibration
factors (sensitivity) of other compounds at a specific m/z
ratio were calculated, taking into account the kinetic reaction
constant (k) for the proton-transfer reaction in the drift tube
and transmission efficiency factors of the quadrupole mass
spectrometer [11]. For several compounds the reaction
constant is known; acetonitrile (m/z 42) has k = 5.1 ×
10−9 cm3 s−1. Concentrations of the compounds which are not
identified have been calculated based on a ‘standard’ reaction
constant for protonation of k = 2.2 × 10−9 cm3 s−1. This
allows a first estimate of the respective concentration of an
unknown compound (based on the measured count rate).
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Table 1. Demographic data (mean ± SD) of subjects by GOLD stage.
Stage Age (yrs) Pack yearsa FEV1b FEV1/FVC (%) Dlcob Dlco/VAb
FEV1/FVC  0.70 61.3 ± 5.1 38.0 (29.7–46.2) 100.8 ± 14.2 76.3 ± 4.1 95.6 ± 13.1 92.3 ± 15.0
GOLD I 62.7 ± 5.2 38.3 (29.7–46.2) 93.2 ± 9.9 64.6 ± 4.3 82.2 ± 20.0 72.9 ± 16.9
GOLD II 65.4 ± 6.2 46.2 (38.7–49.7) 70.3 ± 7.4 59.2 ± 6.7 78.7 ± 19.5 75.9 ± 18.7
GOLD III 61.8 ± 6.4 38.0 (34.2–43.7) 49.9 ± 3.5 44.0 ± 7.6 61.9 ± 4.3 59.9 ± 3.1
a Median (25–75%).
b As percentage predicted.
The limit of detection (LOD) is considered from a
signal-to-noise ratio (S/N) of 2 accordingly to LOD = 2 ×
SDblank/sensitivity. The SDblank represents the standard devi-
ation of the background count rates determined by SDblank =
(Iblank/τ )1/2, where Iblank is the intensity of the background
signal (counts per second) and τ is the dwell time (1.5 s) [11].
The background signal was measured 2 × 3 cycles with the
catalyst in the sampling line (clean air).
The Tedlar bags were tested earlier with respect to
suitability for breath sampling and storage [24]. The collection
method and the chemical analysis were validated for accuracy,
precision, selectivity, limits of detection, sensitivity and
reproducibility and last degradation of VOCs in the collection
bag [24].
2.5. Statistics
We calculated means, standard deviations and 95% confidence
intervals (CI) for normal distributed parameters and medians
with the interquartile range for non-normal distributed ones.
Suitable markers from the spectrum were selected using
stepwise forward logistic regression [25]. However, the ∼150
mass numbers measured deliver an unfavorable case/variable
ratio and the outcome of the logistic regression can be unstable.
We approached this problem via bootstrapping, which takes
a sample with replacement from the database and the logistic
regression is run on that sample [26]. The p-value for entry
was set at 0.15 and for removal at 0.30 in this initial selection
phase. The outcome is a set of mass numbers that discriminate
between ‘emphysema’ and ‘no emphysema’, and this set is
stored. This procedure was repeated 500 times, generating 500
sets of markers. Now, stable and suitable markers will appear
often in these 500 sets (ideally 100%): the occurrence of each
mass number in the 500 sets was therefore calculated. The
markers with a50% occurrence were selected and subjected
to a confirmatory logistic regression.
This confirmatory logistic regression estimated the
probability of an individual to belong to the diseased group,
and these probabilities were used to calculate the area under
the receiver operating characteristic curve (ROC): that area
Table 2. Median (25–75% range) emphysema scores broken down
by GOLD stage. Emphysema scores are depicted as the percentage
lung volume < −950 HU.
Emphysema score (%)
FEV1/FVC  0.70 0.18 (0.06–0.38)
GOLD I 0.51 (0.21–1.15)
GOLD II 1.27 (0.49–2.23)
GOLD III 3.98 (3.61–6.25)
renders the probability to diagnose emphysema or lowered
FEV1/FVC and Dlco/VA values correctly.
Next to the above, a number of other statistical methods
are available [27–29], and in the supplementary data (available
at stacks.iop.org/JBR/5/046009/mmedia), we present the
outcome of such methods. The advantage of this approach is
that results obtained here are validated via alternative methods.
3. Results
A cohort of 204 subjects was recruited for this study; the
characteristics are shown in table 1. Fifty-three subjects
were classified as GOLD I, 25 as GOLD II and five subjects
as GOLD III. No GOLD IV subjects were found. The
median ES according to the GOLD stage are given in
table 2. Of all subjects, 54.4% (95% CI 47.4–61.3%)
still smoked; the smoking/non-smoking ratio in the groups
with a lowered/normal FEV1/FVC was not different (p =
0.766), nor was it in the group with/without emphysema
(p = 0.199).
Acetonitrile, measured with PTR-MS at m/z 42, is a
known indicator for smoking, and it indeed discriminated well
between ex- and current smokers (p < 0.001) (see table 3)
[30]. The ROC area was 0.831 (95% CI 0.770–0.891).
Emphysema was diagnosed in 43 subjects (21.1%, 95%
CI 16.0–27.2%). The bootstrapping approach delivered m/z
87 as a marker (table 4). The median levels for m/z 87 in
emphysema subjects are higher, but the overlap in values is
considerable. The ROC area to detect emphysema was 0.558
(95% CI 0.453–0.662).
Table 3. Median (25–75% range) of m/z 42 (acetonitrile) levels broken down by smoking status.
LOD (ppbv) Median levels (25–75% range)
m/z p-valuea Current smoker (ppbv) Ex-smoker (ppbv)
42 0.31 <0.001 726 (358.3–1078) 116 (74.6–188.3)
a p-values from the confirmatory logistic regression.
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Table 4. Suitable m/z to detect emphysema (levels in normalized counts/sec).
LOD (ppbv) Median levels (25–75% range)
m/z p-valuea No emphysema (ppbv) Emphysema (ppbv)
87 1.31 0.06 16.8 (6.2–34.3) 26.9 (6.1–44.2)
a p-values from the confirmatory logistic regression.
Table 5. Suitable m/z to detect an abnormal FEV1/FVC.
LOD (ppbv) Median levels (25–75% range)
m/z p-valuea Normal FEV1/FVC (ppbv) Abnormal FEV1/FVC (ppbv)
52 0.47 0.007 2.6 (1.3–3.2) 2.1 (1.3–3.1)
135 0.82 0.002 1.8 (1.2–2.6) 2.2 (1.4–3.1)
a p-values from the confirmatory logistic regression.
Table 6. Suitable m/z to detect an abnormal Dlco/VA.
LOD (ppbv) Median levels (25–75% range)
m/z p-valuea Normal Dlco/VA (ppbv) Abnormal Dlco/VA (ppbv)
122 0.82 0.046 2 (1.3–2.5) 1.6 (1–2.2)
a p-values from the confirmatory logistic regression.
Eighty-three subjects (40.7%, 95% CI 34.2–47.5%)
showed a FEV1/FVC value below the lower limit of normal.
The bootstrapping approach delivered m/z 52 and m/z 135
(table 5). The levels of m/z 52 are reduced in obstruction,
but m/z 135 is not. The ROC area to detect an abnormal
FEV1/FVC of this combination of markers was 0.646 (95%
CI 0.562–0.730).
Seventy-one (34.8%, 95% CI 28.6–41.6%) showed a
Dlco/VA value below the lower limit of normal. The
bootstrapping approach delivered m/z 122 as a marker
(table 6), which was reduced in diseased subjects. The ROC
area to detect an abnormal Dlco/VA was 0.671 (95% CI 0.524–
0.710).
It is known that identification of compounds is notoriously
difficult with PTR-MS, as one mass-to-charge ratio may be
associated with a parent molecule, fragment of the parent
molecules and/or clusters between water and small molecules
with strong permanent dipole moments. A list with possible
candidates for the four mass-to-charge ratios of interest for
this study is given in table 7. When known, the fragmentation
ions are also specified.
A possible compound for m/z 52 is chloramine (H2NCl).
For subjects with abnormal FEV1/FVC, the identity of the ion
at m/z = 52 as chloramine is confirmed by the presence of
the isotopic ion m/z = 54 with an intensity of 6.5% which is
close to the expected isotopic abundance of 7.2% (correlation
coefficient of 0.8).
The ion m/z 87, found as a marker for emphysema, is
the parent ion of 2,3 butanedione (diacetyl), 2-or 3-pentanone,
2-or 3-methylbutanal (table 7). Apart from these, several other
substances (not listed in the table) are suggested to be present
in exhaled breath. In our instrument as well as in other reported
studies [31, 32], the main contributions to these compounds
are attributed to m/z 87 and 69. For the emphysema subjects,
the related percentage contributions for the ion traces at m/z
Table 7. List of possible compounds for the m/z markers indicated
in tables 4–6.
Possible compounds Related ions References
m/z 87
Pentanal 69, 87, 41 [45, 32, 33]
2,3-butanedione 87, 61, 88, 43 [46]
2-methyl-3-buten-2-ol (MBO) 87, 69, 41 [31, 32]
2-methylbutanal 87, 69 [31]
2-pentanone 87, 45, 88 [33], [32]
3-methyl-2-butanone 87, 88 [32]
3-methyl-2-buten-1-ol 87, 69, 41 [31]
3-methyl-3-buten-1-ol 87, 69, 41 [31]
3-methylbutanal 87, 69 [31]
3-pentanone 87, 69 [32]
m/z 52
Propiolonitrile [37]
Chloramine [47]
m/z 122 [37]
Benzamide
2,6-dimethyl-benzenamine
4-aminobenzenecarbonal
1-(4-pyridinyl)-ethanone
1-(3-pyridinyl)-ethanone
n-ethyl-benzenamine
Benzeneethanamine
N,N-dimethyl-benzenamine
2-propyl-pyridine
2-(1-methylethyl)-pyridine
Other alkyl homologs [36]
m/z 135 [32, 37]
sec-butylbenzene
1,2,3-trimethylbenzene
1,3,-diethylbenzene 135, 79
1,4,-diethylbenzene
n-butylbenzene
1,2,-diethylbenzene
1,2,3,5-tetramethylbenzene [48]
1,2,4,5-tetramethylbenzene
In bold are the major fragments.
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87 and 69 are 80% and 20%, respectively, and the linear
correlation coefficient between the two ions of 0.8. Hence, we
indicate as the most probable candidate 2-methylbutanal and
exclude several compounds with m/z 69 as the major fragment,
such as pentanal, 2-or 3- methyl-2- or 3-buten-1 or 2-ol, etc.
For ketones such as 2,3 butanedione or 2-pentenone,
hardly any fragmentation is reported so far. The protonated
molecular ion is the most abundant mass, often followed by
the isotopic ion [33]. In the emphysema patients, a weak
correlation was found between m/87 and m/z 88 (linear
correlation coefficient of 0.3). Moreover, the isotopic ion at
m/z 88 is highly influenced by the presence of N,N-dimethyl-
acetamide, a compound released by the Tedlar bags [24].
Based on these considerations, we cannot assess m/z 87 to
any of the two ketones mentioned above.
Peroxyacetyl nitrate (PAN) was reported as a possible
source of m/z 122 in selected ion flow tube mass spectrometry
(SIFT-MS) [34] using H3O+ as primary ions. However, in the
PTR-MS m/z 122 undergoes subsequent reaction with water,
and therefore, m/z 77 is used instead for PAN detection [35].
Possible compounds for m/z 122 are the alkyl homologs as
found in breath analysis with PTR-MS [36, 37].
The ion m/z 135 is attributed to alkyl benzene compounds
[32] (table 7).
4. Discussion
Markers in exhaled breath appear to be weakly related to
emphysema and pulmonary function outcome in this screening
setting. In other settings, more favorable characteristics
and/or markers may be found [38].
The challenge in the field of exhaled VOCs is the selection
of suitable markers from a wide range, which can be done
based on an in-depth knowledge of the inflammatory processes
and the VOCs generated. This requires prior definition of
markers and often represents an educated guess (candidate
marker approach). A scanning approach, like in genetic
genome wide scans, can be more fruitful. One of the problems
of this approach is that the outcome can be highly sample
dependent, due to the unfavorable case/parameter ratio [39].
One way to deal with that problem is to chart the degree of
sample dependence via bootstrapping. As said, bootstrapping
draws many samples from a dataset and in some the effects of
e.g. influencing data points will be present. In such samples,
the outcome is vastly different, and therefore we selected
markers with a high prevalence in the bootstrap samples.
Bootstrapping is also known to lead to a better extrapolation
of the results, as the sampling error is reduced. The fact
that a well-known smoking marker (m/z 42) discriminated
ex- from current smokers is reassuring and validates both the
measurement system and the statistical approach [30]. Still,
it is possible that this technique is less well suited for the
purpose, therefore we decided to use several other methods,
described in the supplement; none of these alternatives lead
to another conclusion (for details, see the supplementary data
available at stacks.iop.org/JBR/5/046009/mmedia).
Confounders (e.g. recent smoking, food, etc) may
bias the outcome. However, smokers and ex-smokers are
randomized over the emphysema/non-emphysema and over
obstructed/non-obstructed groups. The smoking status was
obtained before CT-scanning and pulmonary function tests
were carried out. Smoking bias is therefore improbable.
Further proof of a lack of (recent) smoking bias is that the
smoking indicator acetonitrile does not appear as a marker in
any of our analysis [30]. Similar arguments can be used to
exclude food or other effects. Diseases such as lung cancer or
α1-antitrypsin deficiency are also randomized over the groups
as their presence was unknown at the time of sampling or
their effects are negligible as these diseases are seldom in
the general population (∼1% of all COPD cases are due to
α1-antitrypsin deficiency). All materials in contact with the
in-/exhaled air were inert/non-absorbable, and hence they can
also not influence the outcome.
As we aimed to detect emphysema within (former) heavy
smokers, we did not include healthy (non-smoking) controls.
The contrast between the groups studied would increase,
favoring marker detection, but at the same time outcome would
be difficult to extrapolate to COPD screening in smokers.
Furthermore, a possible bias due to differences is smoking
habits would have been introduced.
Despite a lack of bias and the sensitive measurements, we
must conclude that the one emphysema marker we report is not
a strong one. The area under the ROC (AUC) of 0.558 does not
constitute a suitable marker: a 0.7 value is often considered as
a minimum. For obstruction and gas-exchange problems, the
results were slightly better, but still these markers also did not
reach the 0.7 threshold. Furthermore, m/z 87 which is most
probably assessed to 2-methylbutanal is weakly correlated
with m/z 42 (r = 0.272), indicating that it is not related to
smoking.
There can be several explanations for the low AUCs of
the ROC. First of all, the emphysema severity in this non-
hospital-based cohort was limited, since severe COPD was an
exclusion criterion for participation. Emphysema is a slow-
developing disease and the amount of inflammation causing it
can be low grade, and so the probability of exhaling distinct
fingerprints will be equally low. We could have included
subjects with severe emphysema, but as these constitute more
advanced disease, we consider that approach as less useful.
Emphysema needs to be addressed in an early stage to be
able to prevent further deterioration. A recent cross-sectional
case-control study with e-Nose reported a good discrimination
between asthma and COPD, but not between COPD and non-
smoking controls [40]. The COPD subjects in that study
were characterized by severe obstruction (post-bronchodilator
FEV1 57% of predicted) and are much more diseased than the
subjects included in this study. We therefore propose as an
explanation that COPD/emphysema in heavy smokers do not
generate sufficiently different exhaled VOC profiles to be used
as markers.
The second explanation can be that we used an unbiased
selection of heavy smokers. Other exhaled breath studies
on e.g. lung cancer, which report suitable markers, often
used a case-control design [41, 42]. In such a design,
diseased subjects are contrasted to healthy subjects in equal
numbers, mostly after matching. Such a design modifies the
5
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characteristics by increasing the prevalence of disease and
hence the contrast: it will be easier to find markers in such
a high-contrast study. In screening studies, the prevalence of
the disease is much lower, and it becomes much more difficult
to select a few subjects amongst many non-diseased subjects.
The lower the prevalence of a disease, the stronger the marker
for disease must be or the less the overlap in marker values
between groups to be able to detect the diseased subjects.
The third possible explanation lies in the type of
instrument used. PTR-MS is suitable for detecting only a small
amount of masses with satisfactorily speed and low detection
limit (mass range up to 160 amu). Compounds with higher
molecular weight which could be potential candidates are thus
not considered. The identification of compounds measured
by PTR-MS is always tentative. Alternative solutions to
overcome these limitations include the use of ion traps,
coupling of PTR-MS with GC, the very recently developed
time-of-flight mass spectrometry in combination with PTR-
MS and the analytical techniques such as GC-MS or SIFT-
MS [43, 44]. However, in this discovery phase, this is not a
disadvantage [40].
To summarize, in COPD and/or emphysema screening
studies, exhaled VOCs have not provided valuable diagnostic
information so far.
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